Rigel Pharmaceuticals Inc (FRA:RI2) Stock Price & 30 Year Financial Data
This article provides 30-year financial data for Rigel Pharmaceuticals Inc (FRA:RI2), including growth rates for revenue, EPS, EBIT, EBITDA, free cash flow, dividends, and book value. It also lists key financial metrics such as market cap, enterprise value, PE ratio, and PB ratio. The data is presented with disclaimers regarding its use as investment advice.
RIGL PE Ratio & Valuation, Is RIGL Overvalued
Rigel Pharmaceuticals Inc (RIGL) is currently considered undervalued, with its fair price estimated between $30.81 and $78.62, compared to its current price of $27.53. The company's current forward PS ratio of 1.59 is also seen as undervalued relative to its five-year average. RIGL's P/S ratio is below the industry average, and its robust revenue growth of 21.19% suggests this valuation could be sustainable.
Rigel Pharmaceuticals (RIGL) seeks approval for equity plan share increases at 2026 meeting
Rigel Pharmaceuticals is asking stockholders to approve several proposals at its upcoming 2026 annual meeting on May 14, 2026, including the election of three directors, amendments to its 2018 Equity Incentive Plan and 2000 Employee Stock Purchase Plan to increase authorized shares, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as its independent auditor. The proposed equity plan changes involve adding 500,000 shares to the 2018 Equity Incentive Plan and 360,000 shares to the 2000 Employee Stock Purchase Plan, which the company argues are crucial for attracting and retaining talent, aligning executive interests with stockholders, and supporting continued growth without relying on capital-raising dilution. As of March 19, 2026, there were 18,480,019 shares of common stock outstanding and entitled to vote, and the board unanimously recommends voting "FOR" all five proposals.
How (RIGL) Movements Inform Risk Allocation Models
This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) using AI models to inform risk allocation. It highlights a near-term strong sentiment potentially leading to long-term positive bias, noting elevated downside risk due to a lack of additional long-term support signals. The analysis provides specific institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with entry zones, targets, and stop losses, alongside multi-timeframe signal analysis.
Rigel Pharmaceuticals Balances Breakout Growth With Caution
Rigel Pharmaceuticals reported strong Q4 2025 earnings with a 60% jump in annual net product sales and a doubled cash balance, driven by its three-product portfolio. While the company achieved record quarterly sales and profitability, management cautioned that significant noncash tax benefits and one-time growth tailwinds influenced the headline figures. Rigel also highlighted promising early-stage clinical data for R289 in MDS and outlined a conservative 2026 outlook, balancing growth with a realistic assessment of market challenges and investment needs.
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57
H.C. Wainwright analyst Joseph Pantginis has reaffirmed a Buy rating for Rigel Pharmaceuticals (RIGL.US) and maintained a target price of $57. According to TipRanks data, Pantginis has a 48.0% success rate with an average return of 16.8% over the past year. TipRanks provides independent analysis of financial analysts' recommendations, including success rates and average returns.
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
Rigel Pharmaceuticals announced the publication of final data from the Phase 1/2 ARROW study for GAVRETO (pralsetinib) in patients with RET fusion-positive non-small cell lung cancer (NSCLC) in the Journal of Clinical Oncology. The data, which includes an additional 42 months of follow-up, shows robust and durable responses with a manageable safety profile, reinforcing pralsetinib's potential as a first-line treatment. Key findings highlight a 70% overall response rate in patients with measurable disease and significant median overall survival.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of "Moderate Buy" from Brokerages
Rigel Pharmaceuticals (NASDAQ:RIGL) has received a "Moderate Buy" consensus rating from six brokerages, with an average one-year price target of $45.67. Despite missing quarterly EPS estimates, the company exceeded revenue expectations at $69.8 million. Insider Walter H. Moos recently sold 4,000 shares, reducing his stake by nearly 24%, while institutional investors hold 66.23% of the stock.
Jim Cramer Blesses Rigel Pharmaceuticals as a Spec as “It’s Doing Better Than People Realize”
Jim Cramer endorsed Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) as a speculative buy, noting its performance exceeds public perception despite market challenges. The biotechnology company focuses on therapies for hematologic disorders and cancer, with treatments for immune thrombocytopenia and acute myeloid leukemia, and is also developing new inhibitors for autoimmune and inflammatory diseases. Cramer stated, "I bless it as a spec," highlighting its potential for investors willing to take on some risk.
Vanguard realignment leads to 0 shares reported for Rigel (RIGL)
The Vanguard Group has reported 0 shares beneficially owned of Rigel Pharmaceuticals Inc (RIGL) Common Stock, representing 0% of its class, according to a Schedule 13G/A SEC filing. This change is attributed to an internal realignment effective January 12, 2026, which now requires certain Vanguard subsidiaries to report their holdings separately. The filing specifies that neither a sale nor a divestiture occurred, but rather a structural change in how Vanguard's various entities disclose their beneficial ownership.
Rigel Pharmaceuticals (RIGL) Q4 earnings miss estimates
This article reports that Rigel Pharmaceuticals (RIGL) missed its earnings estimates for Q4. No further details are available in the provided content.
Rigel Pharmaceuticals (RIGL) Q4 earnings miss estimates
Rigel Pharmaceuticals (RIGL) reported its Q4 earnings, missing analyst estimates. This article likely details the financial performance and key figures that led to the earnings miss.
Rigel Pharmaceuticals shows rising relative strength; still shy of key benchmark
Rigel Pharmaceuticals (RIGL) saw its Relative Strength (RS) Rating improve to 71, up from 68, indicating it's now outperforming 71% of all stocks. While this is a positive trend, the stock has not yet reached the desirable 80 RS Rating typically associated with top-performing stocks. Investors often seek stocks with an 80 or higher RS Rating as they begin their major price advances.
Rigel Pharmaceuticals shows rising relative strength; still shy of key benchmark
Rigel Pharmaceuticals (RIMG) is showing improved relative strength, with its IBD Relative Strength Rating increasing from 67 to 72. Despite this positive movement, the stock remains below a key benchmark, still trading below its 50-day moving average.
Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update
Rigel Pharmaceuticals, Inc. announced a conference call and webcast to report its second quarter 2025 financial results. The event will take place on Tuesday, August 5, 2025, after market close, with a live conference call and webcast at 4:30 p.m. Eastern Time to discuss results and provide a business update. The webcast will be available on the Investor Relations section of Rigel's website for replay.
Rigel Pharmaceuticals (NASDAQ:RIGL) Rating Lowered to "Hold" at Wall Street Zen
Wall Street Zen has downgraded Rigel Pharmaceuticals (NASDAQ:RIGL) from a "buy" to a "hold" rating, though the consensus rating for the company remains a "Moderate Buy" with an average target price of $45.67. This comes after Rigel reported Q4 EPS of $1.14, missing estimates, while revenue slightly exceeded expectations. The stock saw a dip following the news, and director Walter H. Moos sold 4,000 shares.
Assessing Rigel Pharmaceuticals (RIGL) Valuation After Strong Q4 And Full Year 2025 Earnings Results
Rigel Pharmaceuticals reported strong Q4 and full-year 2025 earnings with US$69.8 million revenue and US$268.07 million net income. Despite this, recent share price performance has been weak, even though longer-term returns remain positive. The company's valuation, currently at US$28.87, suggests it is significantly undervalued compared to analyst targets and intrinsic value estimates, driven by anticipated growth in its commercial portfolio, although risks related to revenue growth and clinical trials exist.
Assessing Rigel Pharmaceuticals (RIGL) Valuation After Strong Q4 And Full Year 2025 Earnings Results
Rigel Pharmaceuticals (RIGL) reported strong Q4 and full year 2025 earnings with significant revenue and net income. Despite recent share price weakness, the company is considered undervalued at $28.87 compared to a narrative fair value of $51.60, driven by long-term earnings power and portfolio expansion including accelerated sales of TAVALISSE, GAVRETO, and REZLIDHIA.
[8-K] RIGEL PHARMACEUTICALS INC Reports Material Event | RIGL SEC Filing - Form 8-K
Rigel Pharmaceuticals Inc. (RIGL) filed an 8-K report detailing its strong financial results for the fourth quarter and full-year 2025, driven by its hematology and oncology portfolio. The company reported significant increases in total revenues and net product sales, alongside a substantial non-cash deferred income tax benefit which boosted net income. Rigel also provided a positive outlook for 2026, anticipating continued revenue growth and positive net income while advancing its clinical pipeline, particularly the Phase 1b study of R289.
Rigel Pharmaceuticals (RIGL) EPS Spike On Non Cash Gains Challenges Bullish Narratives
Rigel Pharmaceuticals (RIGL) reported Q4 FY 2025 revenue of US$69.8 million and EPS of US$14.72, with trailing twelve-month EPS of US$20.40 driven by US$367.0 million in net income. However, a significant portion of this earnings surge is attributed to non-cash items, raising questions about the durability of its profitability. Despite a low P/E ratio and a high DCF fair value, analysts forecast a 33.2% annual earnings decline over the next three years, challenging bullish narratives centered on strong cash generation and cost control.
Rigel Pharmaceuticals (NASDAQ:RIGL) Posts Quarterly Earnings Results, Misses Estimates By $0.19 EPS
Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $1.14 EPS, missing analyst estimates by $0.19, despite revenue of $69.80 million which slightly exceeded expectations. The biotechnology company showcased strong commercial momentum in 2025 with $232 million in net product sales and improved liquidity, but its stock declined by 2.2% following the announcement. Analysts currently rate RIGL as a "Moderate Buy" with a consensus target price of $45.67.
Rigel Pharmaceuticals’ Fast Track Ambitions Face Significant FDA Uncertainty
Rigel Pharmaceuticals is facing significant uncertainty regarding its pursuit of FDA fast track designation for its product candidates. The FDA has broad discretion and may decline such requests, even if similar products have previously received the designation. Additionally, even if fast track status is granted, it does not guarantee accelerated development, priority review, or eventual marketing approval, leaving regulatory timelines and outcomes unclear.
Rigel Pharmaceuticals (RIGL) EPS Spike On Non Cash Gains Challenges Bullish Narratives
Rigel Pharmaceuticals (RIGL) reported strong FY 2025 results with a significant EPS jump, largely driven by non-cash gains, which raises questions about the durability of its profitability. Despite a low P/E ratio and a high DCF fair value, analysts forecast a substantial annual earnings decline over the next three years, contrasting with the modest revenue growth. The article highlights both bullish arguments focusing on operational leverage and pipeline funding, and bearish concerns regarding the impact of non-cash items, revenue growth, and product concentration.
Rigel Pharmaceuticals (RIGL) Projects Revenue Decline for 2026
Rigel Pharmaceuticals (RIGL) is anticipating a revenue decline in 2026, with total revenue projected to decrease by approximately 4% to between $275M and $290M, primarily due to a significant drop in contract revenue despite expected growth in net product sales. The company's financial health presents a mixed picture, showing strong profitability and liquidity but also warning signs like a distress-level Altman Z-Score and potential financial manipulation suggested by the Beneish M-Score. Despite these concerns, RIGL exceeded Q4 2025 earnings expectations and its shares trade within reasonable historical valuation ranges, with analysts predicting potential upside.
Rigel Pharmaceuticals (RIGL) Set to Report Q4 FY2025 Earnings After the Bell — Here’s What to Expect
Rigel Pharmaceuticals (RIGL) is scheduled to report its Q4 and full-year 2025 earnings after market close, with estimates pointing to significant revenue and EPS growth driven by TAVALISSE royalties. The article highlights key metrics to watch, including full-year revenue against the $299M estimate, EPS to confirm profitability inflection, TAVALISSE royalty trajectory, and operating expense discipline. Analysts hold a consensus "Strong Buy" rating for the stock, with a divided price target of $43.20.
Rigel Pharmaceuticals (RIGL) Set to Report Q4 FY225 Earnings After the Bell — Here’s What to Expect
Rigel Pharmaceuticals (RIGL) is scheduled to report its Q4 and full-year 2025 earnings after the market closes on March 3, 2026. The company is transitioning into a profitable royalty and commercial operation, driven by growing TAVALISSE royalties. Analysts expect significant revenue and EPS growth, with key metrics to watch including full-year revenue, EPS, TAVALISSE royalty trajectory, operating expenses, and new pipeline developments to confirm the sustainability of its profitability inflection.
Rigel Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Rigel Pharmaceuticals Inc has reported its earnings summary for the quarter that ended on December 31. The brief report, provided by Refinitiv and Reuters, covers the financial results for the pharmaceutical company, with further details likely available to registered users.
Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates
Rigel Pharmaceuticals (RIGL) reported Q4 earnings of $1.14 per share, missing the Zacks Consensus Estimate of $1.33 per share, despite revenues of $69.8 million matching estimates. The company's shares have underperformed the S&P 500 year-to-date, and its earnings outlook is currently rated as a Zacks Rank #3 (Hold). The article also mentions Vivos Therapeutics, Inc. (VVOS) as another stock in the same industry.
Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates
Rigel Pharmaceuticals (RIGL) reported Q4 earnings of $1.14 per share, missing the Zacks Consensus Estimate of $1.33, despite an increase from $0.8 per share a year ago. The company's revenues for the quarter were $69.8 million, aligning with estimates, and its stock has seen a significant decline year-to-date. The outlook for Rigel is currently a Zacks Rank #3 (Hold), influenced by a mixed trend in estimate revisions.
RIGL: Future Returns Will Reflect Elevated 2026 Guidance And Lower Risk Profile
Analysts have increased their price target for Rigel Pharmaceuticals (RIGL) due to updated assumptions regarding long-term revenue growth, profit margins, and a higher future P/E multiple, suggesting confidence in the company's potential. Despite some bearish concerns about execution risk and sensitivity to competitive outcomes, Rigel's updated 2026 guidance and positive clinical trial updates for R289 contribute to the optimistic outlook. The fair value remains at $51.6, implying the stock is undervalued, with an increased discount rate and slightly higher revenue growth assumptions.
A Preview Of Rigel Pharmaceuticals's Earnings
Rigel Pharmaceuticals (NASDAQ: RIGL) is scheduled to release its quarterly earnings report on Tuesday, March 3, 2026, with analysts forecasting an EPS of $1.25. The company has a history of surpassing EPS estimates, which has positively impacted its stock price. Investors are keen on the upcoming report for both results and future guidance, especially given the stock's positive performance over the last year.
(RIGL) and the Role of Price-Sensitive Allocations
This article provides an in-depth stock analysis for Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), highlighting neutral near and mid-term readings but a positive long-term bias. It outlines institutional trading strategies including position, momentum, and risk-hedging, along with multi-timeframe signal analysis, and AI-generated signals for support and resistance levels. The analysis aims to help investors optimize position sizing and manage drawdown risk.
Rigel Pharmaceuticals Options See Significant Rise in Implied Volatility
Rigel Pharmaceuticals (RIGL) has experienced a significant increase in implied volatility for its options, particularly the March 20, 2026 $10.00 Call option, suggesting market anticipation of substantial price swings. This heightened volatility, combined with a Zacks Rank #3 (Hold) and recent analyst upgrades to earnings estimates, indicates a potential trading opportunity for options traders. The article highlights that while implied volatility signals expected price fluctuations, it's just one factor among analysts' insights.
Implied Volatility Surging for Rigel Pharmaceuticals Stock Options
Implied volatility for Rigel Pharmaceuticals (RIGL) stock options, particularly the March 20, 2026 $10.00 Call, is currently surging, signaling that the market anticipates a significant price movement. Despite the rising implied volatility, analysts currently rate Rigel Pharmaceuticals as a Zacks Rank #3 (Hold) in the Medical - Drugs industry, although earnings estimates for the current quarter have seen an increase. This situation could present potential opportunities for options traders looking to sell premium.
Implied Volatility Surging for Rigel Pharmaceuticals Stock Options
The implied volatility for Rigel Pharmaceuticals (RIGL) stock options, particularly the March 20, 2026 $10.00 Call, has surged, indicating that the market anticipates a significant price movement for the stock. This heightened volatility, combined with Rigel Pharmaceuticals' Zacks Rank #3 (Hold) rating and recent upward analyst earnings estimate revisions, suggests a potential trading opportunity for options traders. Options traders often use high implied volatility to sell premiums, banking on the stock not moving as much as expected by expiration.
Implied Volatility Surging for Rigel Pharmaceuticals Stock Options
Implied volatility for Rigel Pharmaceuticals (RIGL) stock options is surging, particularly for the March 20, 2026 $10.00 Call, suggesting that the market expects a significant price movement. Despite the high implied volatility, analysts currently rate Rigel Pharmaceuticals as a Zacks Rank #3 (Hold) in the Medical - Drugs industry, with recent positive revisions to earnings estimates. This situation may present a trading opportunity for seasoned options traders who look to sell premium.
Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: Should You Buy?
Rigel Pharmaceuticals (RIGL) is projected to show a year-over-year increase in earnings and higher revenues for the quarter ended December 2025. The article discusses earnings expectations, recent estimate revisions, and introduces the Zacks Earnings ESP model to assess the probability of an earnings beat or miss. While Rigel's Earnings ESP suggests analysts are slightly bearish, its Zacks Rank of #3 makes a conclusive prediction difficult.
Walter Moos Sells 4,000 Shares of Rigel Pharmaceuticals (NASDAQ:RIGL) Stock
Walter Moos, a Director at Rigel Pharmaceuticals (NASDAQ:RIGL), sold 4,000 shares of the company's stock for a total of $145,440 on February 20th, reducing his stake by 23.92%. Following the sale, Moos now owns 12,722 shares valued at approximately $462,571.92. Rigel Pharmaceuticals has a market capitalization of $626.39 million, a P/E ratio of 5.59, and a consensus "Hold" rating from analysts with an average target price of $43.20.
IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential?
This article compares Iovance Biotherapeutics (IOVA) and Rigel Pharmaceuticals (RIGL), two small-cap biotechs, to determine which offers more upside potential. While IOVA, focused on cancer immunotherapies, experienced a turbulent 2025 despite strong Amtagvi sales, RIGL, specializing in hematologic disorders and cancer, showed strong performance driven by Tavalisse. The analysis concludes that IOVA, despite a higher valuation, might offer a longer growth runway with pipeline catalysts, whereas RIGL's recent rally and competitive pressures might limit its future growth.
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 3, 2026. Following the announcement, Rigel senior management will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. Participants can access the call via phone or live webcast from the company's investor relations website, with the webcast archived for 90 days.
Responsive Playbooks and the RIGL Inflection
This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) through an AI-driven lens, highlighting a near-term positive sentiment amidst a mid-term weak bias and long-term strength. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, and provides multi-timeframe signal analysis and risk-reward ratios. The analysis suggests an exceptional 77.6:1 risk-reward setup targeting a 22.2% gain.
RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell?
Rigel Pharmaceuticals (RIGL) stock has risen 59% in the past year, significantly outperforming the industry, largely driven by strong sales of its drug Tavalisse. Preliminary fourth-quarter and full-year 2025 results show robust revenue growth, and the company projects continued momentum and profitability in 2026 despite competitive pressures from larger drugmakers. Analysts suggest holding the stock due to its growth potential and positive outlook.
RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell?
Shares of Rigel Pharmaceuticals (RIGL) have surged 59% in the past year, significantly outperforming the industry, sector, and S&P 500. This growth is primarily driven by the strong performance of its drug Tavalisse, which accounted for approximately two-thirds of total revenues in Q4 2025, alongside contributions from oncology assets. Despite competitive risks and trading at a slight premium, the company's positive financial guidance for 2026 and increasing analyst estimates suggest continued growth potential, leading to a Zacks Rank #3 (Hold) recommendation.
RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell?
Rigel Pharmaceuticals (RIGL) stock has significantly outperformed its industry, sector, and the S&P 500 over the past year, driven by strong performance from its marketed product Tavalisse and growing contributions from its oncology drugs. The company reported robust preliminary financial results for Q4 and full-year 2025 and projects continued growth in 2026, aiming for positive net income. Despite competitive threats from larger pharmaceutical companies, Rigel's pipeline and positive analyst outlook suggest growth potential, leading to a Zacks Rank #3 (Hold) recommendation.
Reasons to Consider Rigel Pharmaceuticals (RIGL) as a Strong Momentum Stock: Is It Time to Buy?
Rigel Pharmaceuticals (RIGL) is highlighted as a strong momentum stock with a Zacks Rank of #1 (Strong Buy) and a Momentum Style Score of B, demonstrating significant price increases over the last year. Analyst ratings indicate a "Moderate Buy" consensus with price targets ranging from $38 to $71, reflecting confidence in its commercial execution and promising pipeline. Recent corporate developments include new board appointments, projected 2025 revenues of $275 to $290 million, and strategic partnerships, all contributing to a positive growth outlook for the biotechnology company.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Recommendation of "Hold" from Brokerages
Rigel Pharmaceuticals (NASDAQ:RIGL) has received a consensus "Hold" recommendation from seven brokerage firms, with an average 12-month price target of $43.20. The company recently surpassed its quarterly earnings and revenue estimates, reporting strong financial metrics such as a 40.17% net margin and 204.70% ROE. Institutional investors have also shown increased interest in RIGL, with several hedge funds growing their positions in the stock.
Rigel Pharmaceuticals Charts Course Toward Profitability
Rigel Pharmaceuticals is aiming for profitability in 2026, driven by strong preliminary Q4 2025 revenues of $69.8 million and a 2026 revenue forecast of $275 to $290 million. The company has also appointed Michael P. Miller to its Board to enhance commercial capabilities and is progressing with its R289 drug candidate for myelodysplastic syndromes, with initial Phase 1b data expected by year-end 2026. Investors are awaiting audited 2025 full-year results on March 3 for further assessment.
Piper Sandler Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Raises Target Price to $42
Piper Sandler analyst Allison Bratzel has reiterated a "Hold" rating for Rigel Pharmaceuticals (RIGL.US) and significantly increased the target price from $23 to $42. This adjustment comes from an analyst with a reported 64.5% success rate and an average return of 54.3% over the past year, according to TipRanks data. The information is provided for informational purposes only and is not investment advice.
Understanding the Setup: (RIGL) and Scalable Risk
This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), indicating weak near and mid-term sentiment despite a positive long-term outlook. It highlights a unique 79.6:1 risk-reward setup targeting a 23.1% gain with minimal risk, and outlines three AI-generated trading strategies for different risk profiles. The analysis provides specific entry, target, and stop-loss levels based on multi-timeframe signal analysis.
Rigel Pharmaceuticals Appoints Michael P. Miller to Board
Rigel Pharmaceuticals has appointed Michael P. Miller to its board of directors, effective February 1, 2026. Miller will serve on the Compensation Committee and receive standard non-employee director compensation, including stock options. Analysts maintain a Buy rating on Rigel stock with a $57.00 price target.
